Send the following on WhatsApp
Continue to ChatWithdrawal of FDA approval for cancer medicine-Umbralisib due to unfavorable benefit-risk profile: USFDA Drug safety communication https://publicsafetyandvigilance.com/2022/06/withdrawal-of-fda-approval-for-cancer-medicine-umbralisib-due-to-unfavorable-benefit-risk-profile-usfda-drug-safety-communication/